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a b s t r a c t
Herpes simplex virus 2 is an important human pathogen as the causative agent of genital herpes,
neonatal herpes, and increased risk of HIV acquisition and transmission. Nevertheless, the only genomic
sequence that has been completed is the attenuated HSV-2 HG52 laboratory strain. In this study we
deﬁned the genomic sequence of the HSV-2 SD90e low passage clinical isolate and a plaque-puriﬁed
derivative, SD90-3P. We found minimal sequence differences between SD90e and SD90-3P. However, in
comparisons with the HSV-2 HG52 reference genome sequence, the SD90e genome ORFs contained
numerous point mutations, 13 insertions/deletions (indels), and 9 short compensatory frameshifts. The
indels were true sequence differences, but the compensatory frameshifts were likely sequence errors in
the original HG52 sequence. Because HG52 virus is less virulent than other HSV-2 strains and may not be
representative of wildtype HSV-2 strains, we propose that the HSV-2 SD90e genome serve as the new
HSV-2 reference genome.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Herpes simplex virus 2 (HSV-2), the major causative agent of
genital herpes, undergoes a primary infection in the genital
mucosa and spreads to sacral ganglia where the virus establishes
a latent infection in sensory neurons. Reactivation of the latent
virus leads to recurrent genital infections and lesions, called
genital herpes. HSV-2 causes life-threatening infections in neo-
nates infected during delivery and increases the risk of HIV
acquisition and transmission (Roizman et al., 2013). Therefore,
HSV-2 is an important human pathogen, and additional antivirals
and a vaccine are needed.
The herpes simplex viruses are large double-stranded DNA
(dsDNA) viruses that replicate in the nuclei of host cells (Roizman
et al., 2013). The HSV genome is a linear dsDNAmolecule comprised of
two covalently linked segments, the long (L) and short (S) segments,
which each consist of unique sequences (UL and US) bounded by
inverted repeats (Hayward et al., 1975) (Fig. 1). Several HSV-1 genomic
sequences have been determined (Macdonald et al., 2012a, b;
McGeoch et al., 1988; McGeoch et al., 1986; Szpara et al., 2010), but
the complete genome of only one strain of HSV-2 has been
determined. The only available HSV-2 genomic sequence, that of the
HG52 laboratory strain (Timbury, 1971), was determined a number of
years ago (Dolan et al., 1998) and deﬁned the genome size as 154,476
basepairs (bps). The HG52 DNA sequence was recently updated by
Andrew Davison and provided in GenBank (JN561323.1), but the
original sequence still serves as the reference genome for HSV-2.
Although there is no complete genome sequence of a low-passage
clinical isolate of HSV-2, sequencing of speciﬁc genes of HSV isolates
gives evidence of at least limited sequence diversity among HSV-2
isolates (Norberg et al., 2007). Sequence analysis of glycoprotein genes
in African and European HSV-2 isolates showed limited sequence
diversity and deﬁned two possible genogroups, one consisting entirely
of African isolates and another containing both European and African
isolates (Norberg et al., 2007). In addition, laboratory strains of HSV-2
show polymorphisms in restriction endonuclease cleavage sites
(Hayward et al., 1975), and there is evidence for differences in
immunological and pathogenic properties of HSV-2 strains from the
United States and South Africa (Dudek et al., 2011).
The NCBI reference sequence strain, HSV-2 strain HG52 (Acces-
sion number NC_001798), shows variable virulence, in that plaque
stocks showed LD50 values ranging from greater than 105 PFU to less
than 103 PFU by cranial inoculation (Taha et al., 1988). When
inoculated peripherally, HSV-2 HG52 seems to be relatively avirulent.
Very limited paralysis was observed when HG52 was inoculated in
mice by the footpad route (Subak-Sharpe et al., 1984). In a study
involving corneal infection of mice, 106–107 PFU of HG52 showed no
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mortality while similar dosages of HSV-2 strains 333 or 186 showed
100% mortality (Mitchell et al., 1990). The LD50 for other HSV-2
strains is in the range of 1–6103 PFU via the vaginal route
(Blakeney et al., 2005; Dudek et al., 2011). Furthermore, unlike other
HSV-2 strains, HSV-2 HG52 is unable to shut off host protein
synthesis. This defect is likely due to a frameshift mutation in the
UL41 gene, which encodes the viral host shutoff protein (Everett and
Fenwick, 1990). Despite the knowledge of the host shutoff defect, the
full genotype of HG52 responsible for the attenuated phenotype is
currently not known.
In total, these considerations highlight the urgent need for a
complete genome sequence of a low passage isolate of HSV-2. In
this study we have generated the complete genome sequence of
an early passage virulent African HSV-2 clinical isolate, SD90e, as
well as a plaque-puriﬁed version of this isolate. We propose that
this new clinical isolate genome could serve as a new HSV-2
reference genome.
Results
Comparison of an HSV-2 early passage genome with the HG52
reference genome.
The HSV-2 SD90 virus, which was isolated at an STD clinic in
South Africa (Lai et al., 2003), has been passaged only a limited
number of times in cell culture and shows high virulence in a
mouse genital model (Dudek et al., 2011), similar to most other
clinical HSV-2 strains (Blakeney et al., 2005; Dudek et al., 2011).
We determined the genomic sequence for an SD90 early passage
isolate, named SD90e, using viral DNA puriﬁed from infected cell
lysates by double banding on sodium iodide (NaI) density gradi-
ents. Illumina sequencing of this sample generated 6000-fold
sequence coverage. Assembly of Illumina data using de novo
assembly programs gave a number of blocks of sequence, or
contigs, as observed for HSV-1 (Szpara et al., 2010). To reﬁne the
assembly and ﬁll in large gaps, we mapped the sequence reads to
the individual UL, US, RL and RS regions containing 200 bp of
overlapping sequence based on the HG52 reference sequence. This
gave 5 large and 3 small contigs. The resulting contigs were used
to manually reconstruct a full genome sequence by (1) mining
Illumina raw reads when necessary to connect the contigs,
(2) generating RL and RS inverted repeats bounding their respec-
tive unique sequences by inverting a copy of each sequence, and
(3) assignment of numbers of repetitive sequences (a sequences)
at the termini and the junction of RL and RS to match the HG52
reference sequence. There was one region in each of the ICP4/RS1,
ICP34.5/RL1, UL36, and ICP0/RL2 ORFs whose sequence was ambig-
uous. We therefore used the primers listed in Table 1 and the
conditions described in “Materials and methods” to PCR-amplify
these regions from SD90e DNA, and we then sequenced the
ampliﬁed DNA by conventional Sanger sequencing. The sequences
in the repeated regions in the ICP4/RS1, ICP34.5/RL1, and ICP0/RL2
ORFs were determined using the primers in Table 1.
The UL36 gene repeats were more refractory in that Sanger
sequencing of the SD90e fragment showed at least 9 copies of the
15 nucleotide repeat (caggggcggctgggg) before the sequence
appeared to move into unique sequences, but the sequence was
not unequivocal. Parallel sequencing of our isolate of HSV-2 HG52
DNA showed 6 copies of the UL36 repeat, in contrast to the 11
copies in the GenBank reference sequence. To attempt to conﬁrm
these numbers of repeats, we analyzed the PCR products in an 8%
polyacrylamide gel (Fig. 2). The SD90e amplimer was approxi-
mately 550 bp, consistent with the 547 bp predicted by 9 copies of
the repeated sequence while the HG52 amplimer was approxi-
mately 500 bp, consistent with the 502 bp predicted by 6 copies of
the repeated sequence. Therefore, we have provisionally described
the UL36 gene of SD90e as having 9 copies of this repeated
sequence, but further analysis is needed to conﬁrm this.
The combination of the Illumina and Sanger sequence analyses
gave a complete SD90e genome of 154,096 basepairs (GenBank
accession number KF781518). We then compared our SD90e
genome assembly with the HSV-2 HG52 reference genome in
GenBank (NC_001798) and the recent HG52 sequence submitted
by Andrew Davison (GenBank accession number JN561323.1,
determined by “sequence of viral DNA and polyA RNA harvested
at 10 h after infection”) using the Genome Annotation Transfer
Utility (GATU) program (Pickett et al., 2012) from the Virus
Pathogen Resource (http://www.viprbrc.org). The SD90e genome
contained more than 100 nucleotide differences within open
reading frames compared to the HG52 reference sequence, but
overall, US was 99.3% conserved and UL was 99.6% conserved
between the two genomes.
Nine ORFs contained a combined total of thirteen indels
(insertions or deletions) (Table 2). These indels were multiples
of 3 nucleotides so the reading frame was not altered. The
original HG52 sequence and the more recent Davison HG52
sequence were identical in these regions (Table 2). Furthermore,
our own sequence of HG52 shows the same indels (results not
shown). Therefore, these indels are likely to be real sequence
differences between SD90e and HG52. Because several of the
affected ORFs encode essential or important viral proteins, we
predict that these changes could account for the reduced viru-
lence of the HG52 virus. For example, the SD90e ICP4 (RS1) gene
encoding the major viral transactivator protein showed three
indels, a 3-codon deletion, a 1-codon insertion, and a 6-codon
insertion (Table 2). The RL2 gene encoding the ICP0 immediate
early protein showed a 20-codon deletion. The UL27 ORF encod-
ing glycoprotein B, which is essential for viral entry, showed a 3-
codon deletion near the amino terminus. The UL32 ORF encoding
an essential DNA packaging protein showed a 2-codon deletion.
The UL49 ORF encoding the VP22 virion tegument protein
showed a 2-codon insertion. The other ORFs affected encode
viral proteins that play important roles in vivo. The RL1 gene
encoding the ICP34.5 antagonist of the cellular interferon
response contained an 8-codon deletion and a 1-codon insertion.
The UL39 ORF encoding the large subunit of ribonucleotide
reductase contained a 3-codon deletion and a 2-codon insertion.
The US8 ORF, encoding the glycoprotein E subunit of the viral Fc
receptor, contained a 3-codon insertion. Finally, the US4 ORF
encoding glycoprotein G contained a 1-codon deletion within the
HSV-2 speciﬁc region. Variation within this region could affect
the ability of the standard HSV-2 reference sera to detect the
HSV-2 speciﬁc antigen in the C-terminus of gG-2.
In addition, there were 9 sequence differences between the
SD90e and HG52 reference sequences that consisted of pairs of
closely spaced single nucleotide indels that change the reading
frame for a short distance before it goes back into the reference
Fig. 1. Diagram of the structure of the Herpes simplex virus genome. The top row
shows the long (L) component and the short (S) component of the HSV genome.
The bottom row shows the unique sequences as a line and the boxes denote the
repeated sequences. UL¼unique long component sequences; US¼unique short
component sequences; RL and R'L¼ inverted repeats bounding the long component;
RS and R'S denote inverted repeats bounding the S component. a¼terminal repeat
also located at the L/S junction.
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reading frame (Table 3). However, comparison of the recent
Davison HG52 sequence and our own HG52 Illumina sequence
data showed that these two HG52 sequences are identical to the
SD90e sequence in these areas (Table 3). Therefore, it is likely that
these differences relative to the original HG52 reference sequence
are due to sequencing errors in the original HG52 sequence.
Comparison of an HSV-2 low passage viral genome with a
plaque-puriﬁed derivative
We also determined the sequence of the genome of the SD90-
3P triply plaque-puriﬁed virus (Dudek et al., 2011) using the same
Illumina sequencing methods as described for SD90e. Comparison
of the SD90e and SD90-3P UL and US sequences showed indels in
homopolymeric sequences in the intergenic sequences and only
two codon changes, UL16V126I and UL31 R22L in the UL and US
ORFs of SD90e. Therefore, the two genomes were nearly identical,
showing that the process of plaque-puriﬁcation of the SD90e virus
resulted in minimal changes to the viral genome.
Discussion
The herpes simplex virus DNA genomes have been difﬁcult to
sequence and assemble because of the high GþC content of the
DNA and the highly repetitive nature of the genomes. Several
HSV-1 genomic sequences have been determined, but the com-
plete genome of only one laboratory strain of HSV-2 has been
determined. Therefore, there has been an urgent need for the
complete genomic sequence of a low passage clinical isolate of
HSV-2, both to conﬁrm the original sequence and to deﬁne the
genome of a fresh clinical isolate. In this study we determined the
genome sequence of a limited passage HSV-2 strain, SD90e,
originally isolated in South Africa, and a plaque-puriﬁed derivative
of this isolate. We found that the UL and US ORFs of the early
passage virus, SD90e, and the plaque-puriﬁed virus differed by just
two nucleotides, which was consistent with our previous results
showing that the pathogenicity, as measured in paralysis dose50
values, were similar for SD90e and SD90-3P (Dudek et al., 2011).
The similarity of the genomes showed that plaque puriﬁcation on
Vero cells did not exert a strong selection pressure on the virus.
Although it is still advisable to restrict the number of viral passages
to limit genetic variation that might be due to selective pressures in
cell culture, these results demonstrate that it is possible to clonally
purify an HSV-2 isolate with minimal genetic changes.
It is important to determine the genome sequence of a low
passage clinical isolate of a virus because extensive passaging of
the virus in cell culture can select for mutations that allow the
virus to replicate more efﬁciently in vitro, yet attenuate virulence
in vivo. For example, laboratory strains of HCMV contain a large
genomic deletion relative to clinical isolates (Cha et al., 1996). We
did not ﬁnd any large deletions in the SD90e genome relative to
the HG-52 genome, and these results and other sequencing that
we have done have not shown any major genomic differences
between lab strains and clinical isolates (unpublished results).
HG52 does contain numerous point mutations and thirteen indels
compared to SD90e. Several of the indels are in ORFs encoding
essential viral replication proteins and nonessential proteins that
are important in HSV pathogenesis in vivo. Some or many of these
changes could be the basis for the attenuated phenotype observed
with HG52 in animal studies.
The HG52 sequence as originally reported contains a number of
sequence differences from SD90e and from the HG52 sequences
recently reported in Genbank by Andrew Davison (JN501323.1)
and our own studies of HG52. The differences could be due to the
heterogeneity in the original HG52 stocks as described above,
but it seems more likely that the differences are the result of
sequencing errors due to the inherent difﬁculty in sequencing the
GþC rich HSV-2 DNA using conventional sequencing techniques.
Although a corrected sequence for HG52 has been posted in
Genbank by Davison, the original HG52 sequence remains as the
reference genome sequence.
HSV-2 genomic sequencing
The approaches used in this study may facilitate further
advances in HSV-2 genomic sequencing. Double banding of viral
DNA in NaI gradients provided a pure substrate for Illumina
sequencing. Illumina sequencing and assembly analyses yielded a
nearly complete genomic sequence with 4 areas of low coverage
and ambiguous sequence. PCR ampliﬁcation using special condi-
tions for high GC DNA and Sanger sequencing provided or
conﬁrmed the sequence of three of these regions, the ICP4/RS1,
ICP34.5/RL1, and ICP0/RL2 ORFs. The repetitive region in the UL36
ORF was tentatively assigned based on Sanger sequencing, but
further analysis is needed to conﬁrm the number of repeats in this
Fig. 2. Sizing of the UL36 PCR amplimers by polyacrylamide gel electrophoresis.
Primers described in Table 1 for UL36 were used to amplify viral genomic sequences
from bp 71,890–72,466 (HG52 reference sequence) in SD90e or HG52 DNAs. The
amplimers were analyzed by electrophoresis in an 8% polyacrylamide gel. Lanes 1
and 4, M¼DNA size markers; Lane 2, HG52 amplimer; Lane 3, SD90e amplimer.
Table 1
Primer sets used in this study.
Amplified region Amplimer size, bpa Forward primer (nt position in HG52) Reverse primer (nt position in HG52)
ICP4/RS1 240 GCGGACGACGAGGAG (150,559–150,573) GTAGCGCGCGTAGAAGG (150,782–150,798)
ICP34.5/RL1 221 CTACGCCGAGCCCAG (416–430) CTGTCGTCCGCCTGG (652–666)
ICP0/RL2 583 AAGAGGCGCGGGTCGG (4430–4445) TGACCGTCTTGTTCACGTAAGGC (4990–5012)
UL36 577 GGAGTCTGCGTCGGAGTGTTC (71,890–71,910) GGCAGTGCCGCCTTCTC (72,450–72,466)
a Size predicted by HG52 GenBank sequence.
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ORF. These regions are often gaps in HSV-2 sequence assemblies so
these primers may be generally useful in closing gaps that arise
frequently in assembled HSV-2 genomic sequences. In total, these
analyses allowed the generation of a complete genomic sequence.
These and further advances in mining of sequences to ﬁll gaps
should allow the generation of the large number of HSV-2 genome
sequences needed for phylogenetic analysis.
Reference strain for HSV-2
HG52 shows signiﬁcant attenuation relative to other HSV-2
strains as described above and contains several indels relative to
SD90e. HG52 also contains a frameshift mutation in the UL41 ORF,
which has been corrected to the WT sequence in the reference
sequence in GenBank (NC_001798). For all of these reasons, HG52
does not seem to be representative of other HSV-2 laboratory
strains and clinical isolates. We propose that a more representative
strain, such as SD90e, should be designated as the reference
genome for HSV-2 for future studies. We have used this virus for
genital infection challenge studies (Dudek et al., 2011), and the
virus is available for other researchers to use as a prototype of a
low-passage HSV-2 virus in vaccine or pathogenesis studies.
The deﬁnition of the genomic sequence of a low passage
clinical HSV-2 isolate will provide the foundation for comparative
sequencing of HSV-2 isolates from different geographic origins,
different diseases and different anatomic sites such as genital
lesions versus meningitis. This will allow a determination of
whether genetic variability of HSV-2 is linked to speciﬁc herpetic
diseases or increased risk of HIV-1 infection. Deﬁnition of the
genetic variability of viral epitopes will also be important in
Table 3
Compensating frameshifts in open reading frames.
Table 2
Insertions/deletions in HG52 versus SD90e genomic sequences.
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assessing the selective pressure of the host immune responses on
viral evolution.
Materials and methods
Viruses
The HSV-2 SD90 virus was isolated from a genital ulcer swab
sample from an HIV-1–negative male attending a sexually trans-
mitted disease clinic in Carletonville, South Africa, in 1995
(Lai et al., 2003). The virus was passaged once in South Africa,
frozen at 70 1C and shipped to the Centers for Disease
Control and Prevention. A frozen sample was provided to the
Knipe laboratory by Ron Ballard (Centers for Disease Control and
Prevention). The study of these viruses received a human subjects
exemption from the Harvard Medical School IRB. The primary
isolate was passaged 3 times on Vero cells at Harvard Medical
School to generate the SD90e or early passage virus. SD90-3P is a
clonal virus derived from SD90 through 3 successive plaque
puriﬁcations on Vero cells (Dudek et al., 2011). HSV-2 strain
HG52 was provided by Bernard Roizman, University of Chicago.
Preparation of viral DNA
Vero cells were infected with the HSV-2 viruses at a multi-
plicity of 1 PFU/cell and incubated at 34 1C for 24 h. The infected
cells were collected, and the HSV-2 DNA was puriﬁed from
infected cell lysates by double banding on sodium iodide gradients
essentially as described previously (Walboomers and ter Schegget,
1976), except that proteinase K was used instead of pronase. In
sequence runs, preparations made in this way gave 75–90% of the
sequence runs aligning with HSV-2 reference genome, which was
higher than other methods of puriﬁcation that were tested (results
not shown).
Methods for sequencing
For conventional Sanger sequencing, HSV-2 sequences were PCR-
ampliﬁed from 300 ng of sodium iodide gradient-puriﬁed viral DNA.
PCR reactions contained 10% DMSO, 0.5 M Betaine (Sigma, B0300),
2.5 mM of each dNTP (NEB,N0446) except for dGTP which was added
as a 1:1 mix of dGTP:7-deaza-dGTP (NEB, N0445), 300 nM of each
forward and reverse primer, and 1.25 units of Ex Taq polymerase
(TaKaRa, RR001A) for each 50 μl reaction. PCR cycling conditions were
set as suggested by the polymerase manufacturer, noting that the
elongation step was always carried out at 68 1C. PCR products were
run on agarose gels to conﬁrm the size and purity of the amplicon. The
DNA was then puriﬁed with a QIAquick PCR puriﬁcation kit (Qiagen,
28106) and sent to GeneWiz, Inc. (Cambridge, MA) for Sanger
sequencing using their GC-rich sequencing protocol. Library construc-
tion and sequencing by 454 and Illumina platforms were performed at
the Broad Institute as described previously (Grad et al., 2012; Lennon
et al., 2010).
Assembly of genomic sequences
For the consensus assembly, Illumina fragment pair data were
ﬁrst processed using ALLPATHS-LG (version R44182) to ﬁnd over-
laps between fragment pairs and ﬁll gaps where no overlap is
present. This created a set of sequencing fragments that consist of
the complete sequence between two ends of a paired read set.
These unpaired ﬁlled fragments were then analyzed using Roche's
runMapping (version vMapAsmResearch-10/14/2011) program
with default parameters and a reference genome, HSV-2 HG52,
which consisted of unique segments and RL and RS segments of the
HG52 genome ﬂanked by a small amount of additional, repetitive,
sequence on each end. The runMapping tool produced a ﬁve-
contig consensus built from the placements of the SD90e ﬁlled
fragment reads to the aforementioned HG52 reference genome.
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